[{"id":"f54e7e6b-bb69-4a1c-88ad-1174200e27c6","acronym":"IOV-EAP 402","url":"https://clinicaltrials.gov/study/NCT05398640","created_at":"2022-06-01T16:00:15.608Z","updated_at":"2025-02-25T14:17:00.566Z","phase":"","brief_title":"Expanded Access Program of AMTAGVI That is Out of Specification for Commercial Release","source_id_and_acronym":"NCT05398640 - IOV-EAP 402","lead_sponsor":"Iovance Biotherapeutics, Inc.","biomarkers":" PD-L1","pipe":"","alterations":" ","tags":["PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Amtagvi (lifileucel)"],"overall_status":"Available","enrollment":"","initiation":"","start_date":"","primary_txt":"","primary_completion_date":"","study_txt":"","study_completion_date":"","last_update_posted":"2025-02-17"},{"id":"89ba88cd-80a1-431f-9a1a-3255d4d165a7","acronym":"NCI-2021-11063","url":"https://clinicaltrials.gov/study/NCT05176470","created_at":"2022-01-04T13:53:34.324Z","updated_at":"2024-07-02T16:35:15.802Z","phase":"Phase 1","brief_title":"Neoadj Admin Autologous Tumor Infiltrating Lymphocytes \u0026 Pembrolizumab for Treatment of Adv Melanoma Patients","source_id_and_acronym":"NCT05176470 - NCI-2021-11063","lead_sponsor":"Richard Wu","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF V600E • BRAF V600 • BRAF V600K","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF V600E • BRAF V600 • BRAF V600K"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • cyclophosphamide • fludarabine IV • Amtagvi (lifileucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 2","initiation":"Initiation: 07/01/2022","start_date":" 07/01/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 12/31/2024","study_completion_date":" 12/31/2024","last_update_posted":"2024-03-07"},{"id":"cfe7d0e3-d8e7-4ac0-b5ec-34f2283813e9","acronym":"C-144-01","url":"https://clinicaltrials.gov/study/NCT02360579","created_at":"2021-01-18T11:14:09.234Z","updated_at":"2024-07-02T16:35:43.303Z","phase":"Phase 2","brief_title":"Study of Lifileucel (LN-144), Autologous Tumor Infiltrating Lymphocytes, in the Treatment of Patients With Metastatic Melanoma","source_id_and_acronym":"NCT02360579 - C-144-01","lead_sponsor":"Iovance Biotherapeutics, Inc.","biomarkers":" BRAF • CTLA4","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF • CTLA4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Amtagvi (lifileucel)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 178","initiation":"Initiation: 09/01/2015","start_date":" 09/01/2015","primary_txt":" Primary completion: 01/15/2025","primary_completion_date":" 01/15/2025","study_txt":" Completion: 01/15/2025","study_completion_date":" 01/15/2025","last_update_posted":"2023-07-12"},{"id":"1178967e-6fdc-4d5c-8369-5c0436081ec8","acronym":"HAITILS","url":"https://clinicaltrials.gov/study/NCT04812470","created_at":"2021-03-23T11:52:25.813Z","updated_at":"2024-07-02T16:35:55.857Z","phase":"Phase 1","brief_title":"Hepatic Arterial Infusion of Autologous Tumor Infiltrating Lymphocytes in Patients With Melanoma and Liver Metastases","source_id_and_acronym":"NCT04812470 - HAITILS","lead_sponsor":"Vastra Gotaland Region","biomarkers":" BRAF","pipe":" | ","alterations":" BRAF mutation • BRAF V600","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e BRAF mutation • BRAF V600"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e melphalan • Amtagvi (lifileucel)"],"overall_status":"Recruiting","enrollment":" Enrollment 6","initiation":"Initiation: 02/06/2023","start_date":" 02/06/2023","primary_txt":" Primary completion: 02/01/2025","primary_completion_date":" 02/01/2025","study_txt":" Completion: 02/01/2030","study_completion_date":" 02/01/2030","last_update_posted":"2023-02-10"}]